Please login to the form below

Not currently logged in
Email:
Password:

Dextroamphetamine

This page shows the latest Dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.

Shire weathers generic Adderall XR challenge

Shire weathers generic Adderall XR challenge

attention deficit-hyperactivity disorder (ADHD) drug Adderall XR (amphetamine and dextroamphetamine).

Latest news

  • Shire's Q3 net profit doubles

    Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

  • Shire ADHD scholarship programme

    use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in

  • New use cleared for Shire ADHD drug

    The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved

  • Malcolm's Market Eye: 28 July to 3 August 2007

    Shire wants the drug to take over from Adderall XR (amphetamine/dextroamphetamine), its blockbuster drug now threatened by generic competition, because in 2009 it loses patent protection.

  • Malcolm's Market Eye, 27 February 2007

    Shire has gained full control over Vyvanse, as it needs a successor to Adderall XR (amphetamine/ dextroamphetamine extended-release), its biggest-selling ADHD drug, which soon loses patent protection.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics